Clinical Trial Update: CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CT-2103 in combination with gemcitabine for metastatic breast cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CT-2103
• Gemzar (gemcitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Breast Cancer, Breast Cancer | Phase 1 | Status: COMPLETED